| abstract |
The present invention relates to Selective Androgen Receptor Degrader (SARD) compounds and pharmaceutical compositions comprising a heterocycle and methods of their use in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers that express androgen receptor, androgenic alopecia or other hyperandrogenism skin diseases, Kennedy's disease, Amyotrophic Lateral Sclerosis (ALS), Abdominal Aortic Aneurysm (AAA), and uterine fibroids, and to reducing androgen receptor-full length (AR-FL) levels in a subject, including pathogenic and/or resistance mutations of AR, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms. |